Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONVERT-AF: Canakinumab to Prevent Recurrence After Electrical Cardioversion in Persistent Atrial Fibrillation
2014-000530-29Phase 2Terminated
- Sponsor
- University Hospital Basel
- Start
- Mar 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Atrial fibrillation (AFib) comparing Canakinumab with Placebo (2 arms). Primary endpoint: Time to recurrence of atrial fibrillation within 6 months after electrical cardioversion. Started Mar 2014; status: terminated.
02
Drugs
canakinumab
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2014-000530-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000530-29.